Challenges for the biopharmaceutical sector posed by US policy – article by Dr. Ute Kilger in European Biotechnology
Article by Dr. Ute Kilger on the pressure exerted by the US government on the biopharmaceutical industry and the consequences.
In the fall 2025 issue of European Biotechnology, BOEHMERT & BOEHMERT partner and patent attorney Dr. Ute Kilger explains the impact of US policy on the pharmaceutical and biotech industries in her article “Challenges for the biopharmaceutical sector posed by US policy”.
Dr. Kilger states that both the US and Europe are facing considerable challenges. Measures taken by the US government, such as the Inflation Reduction Act (IRA), the Orange Book initiative, the planned Most Favored Nation pricing regulation, and the proposed Trump-Lutnick patent tax, could hinder innovation and make investment in small molecule drugs unattractive.
In doing so, US policy favors generic drug entry and puts innovative companies under pressure. European companies are also affected, especially those that are heavily dependent on the US market. The EU is pursuing similar trends but has toned down some proposals following criticism from industry. If Europe acts decisively, it could benefit from the US measures and overtake the US in terms of innovative strength, concludes Dr. Kilger.
The full article by Dr. Kilger in English can be found in the fall issue of European Technology starting on page 33 and is available online here.